Method for restoring male sex drive (libido)

Abstract

The method for restoring male sex drive (libido) using a food supplement for restoring male sex drive (libido) relates to medicine, and more specifically to the pharmaceutical industry producing food supplements for restoring male sex drive (libido) and male sexual function which are based on natural ingredients. The method involves the use of nitric oxide (NO) in terms of L-arginine, pollen or beebread in terms of rutin, drone brood in terms of decenoic acids, a substance containing zinc in terms of zinc, a substance containing vitamin B6 in terms of vitamin B6, horny goat weed in terms of icariin, true or false ginseng root in terms of saponins, and leuzea or crowned saw-wort in terms of ecdysteroids, in various combinations.

Claims

1. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, and horny goat weed, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, and 20 to 150 mg of icariin in said horny goat weed, and administering one said dose daily.

2. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, and ginseng root, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, and 5 to 20 mg of saponins in said ginseng root, and administering one said dose daily.

3. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, and Leuzea or Serratula coronata, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, and 0.1 to 30 mg of ecdysteroids in said Leuzea or Serratula coronata, and administering one said dose daily.

4. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, ginseng root, Leuzea or Serratula coronata, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, 5 to 20 mg of saponins in said ginseng root, and 0.1 to 30 mg of ecdysteroids in said Leuzea or Serratula coronata, and administering one said dose daily.

5. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, horny goat weed, ginseng root, and Leuzea or Serratula coronata, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, 20 to 150 mg of icariin in said horny goat weed, 5 to 20 mg of saponins in said ginseng root, and 0.1 to 30 mg of ecdysteroids in said Leuzea or Serratula coronata, and administering one said dose daily.

6. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, horny goat weed, and ginseng root, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, 20 to 150 mg of icariin in said horny goat weed, and 5 to 20 mg of saponins in said ginseng root, and administering one said dose daily.

7. A method of restoring male sex drive, comprising the steps of: providing L-arginine, pollen, male bee brood, a zinc compound, vitamin B.sub.6, horny goat weed, and Leuzea or Serratula coronata, preparing a composition of said ingredients, each dose of said composition comprising 300 to 1000 mg of L-arginine, 0.3 to 3 mg of vitamin B.sub.6, 40 to 100 mg of rutin in said pollen, 0.4 to 1 mg of decenic acids in said male bee brood, 6 to 60 mg of zinc in said zinc compound, 20 to 150 mg of icariin in said horny goat weed, and 0.1 to 30 mg of ecdysteroids in said Leuzea or Serratula coronata, and administering one said dose daily.

Description

EXAMPLE 1

(1) For 1000 packaging products in capsules of 0.5 g with 100 capsules per pack it is taken a mixture of 50 kg of:

(2) Powdered:

(3) Pollen—5000 g

(4) L-arginine—15000 g

(5) Male bee-brood homogenate—5000 g

(6) Zinc citrate—1000 g

(7) Icariin (Horny Goat Weed extract)—5000 g

(8) Vitamin B6—30 g

(9) True Ginseng root—4500 g

(10) Leuzea root—2500 g

(11) Fillers (lactose)—11970 g

(12) The mixture is stirred in a mixer for 3 hours; then it is encapsulated in a known manner.

EXAMPLE 2

(13) For 2000 packaging products in tablets of 0.5 g with 100 tablets per pack it is taken a mixture of 100 kg of:

(14) Powdered:

(15) Pollen—10000 g

(16) L-arginine—30000 g

(17) Male bee-brood homogenate—10000 g

(18) Zinc citrate—2000 g

(19) Icariin (Horny Goat Weed extract)—10000 g

(20) Vitamin B6—60 g

(21) True Ginseng root—9000 g

(22) Leuzea root—5000 g

(23) Fillers (lactose)—23940 g

(24) The mixture is stirred in a mixer for 3 hours; then it is tableted in a known manner.

(25) This technical result is confirmed by researches conducted in the “Secrets of Longevity” medical center in Penza, which showed high efficiency of the claimed remedy compared to control groups for libido increase.

(26) For the first study we prepared six-component food supplements based on Horny Goat Weed—remedy 1 and Leuzea—Remedy 2

(27) The following compounds in a daily dosage were suggested for study:

Contents of Plant Components in the “Remedy 1”

(28) TABLE-US-00002 Components mg L-arginine 900 Horny Goat Weed in terms of icariin 60 Male bee brood in terms of decenoic acid 1 Pollen or beebread in terms of rutin 48 Zinc citrate in terms of zinc 9 Vitamin B6 1.8

Contents of Plant Components in the “Remedy 2”

(29) TABLE-US-00003 Components mg L-arginine 900 Leuzea root in terms of ecdysteroids 0.15 Male bee brood in terms of decenoic acid 1 Pollen or beebread in terms of rutin 48 Zinc citrate in terms of zinc 9 Vitamin B6 1.8

(30) The study investigated the clinical features of psychogenic erectile disorders and noted mental disorders, the efficacy of “Remedy 1” and “Remedy 2” on the dynamics of sexual function by blood testosterone levels, sexual activity parameters (libido and erection) and psychic emotional status in patients with erectile dysfunction; therapeutic dynamics of remedies was compared.

(31) A clinical study was conducted in 30 men with erectile dysfunction. Inclusion criteria were:

(32) 19-60 years old (age limit was associated with frequent detection in men older than 60 years of the severe cerebral organic and physical illnesses and involution processes);

(33) matching of patient's condition at the time of inclusion to diagnostic criteria of ICD 10 B 52.2—absence of genital response, accompanied by one of the following neurotic disorders: anxiety-phobic (F40); mixed anxiety-depressive disorder (F41.2) and adaptation disorder (F 43.2);

(34) absence of leading organic lesion in pathogenesis of sexual disorder.

(35) The study did not include patients with alcoholism; drug addiction; anatomical deformity of the penis; proven endocrine causes of ED; decompensated somatic diseases; use other treatment agents for ED and drugs that can cause ED.

(36) All patients gave informed consent to participate in the study.

(37) To achieve the objectives of the study, patients by simple randomization technique were divided into 3 treatment groups—two experimental and one control:

(38) Group 1. Experimental group—12 people with erectile dysfunction and combined psychoemotional disorders receiving “Remedy 1” and the traditional psychopharmacotherapy.

(39) Group 2. Experimental group—13 people with erectile dysfunction and combined psychoemotional disorders receiving “Remedy 2” and traditional psychopharmacotherapy.

(40) Group 3. Control group—5 people with erectile dysfunction and combined psychoemotional disorders receiving traditional psychopharmacotherapy.

(41) During clinical and sexual examination extent and dynamics of sexual pathological symptoms during therapy were evaluated by the clinical questionnaire “Sexual Formula for Men” (SFM) and sexual function state questionnaire (Vakina T N 2001).

(42) Laboratory and instrumental examination included complete blood count, urinalysis, hormonal status examination—level of total serum testosterone, as well as transrectal prostate ultrasound. Consultative examination by urologist was performed.

(43) The mental state of the patients was determined by clinical and psychopathological method. Examination of personality characteristics was performed by Mini-Mult questionnaire. Intensity and dynamics of anxiety-depressive disorder symptoms during therapy were evaluated by Hospital Anxiety and Depression Scale (NADS).

(44) Registration of side effects was conducted on UKU scale with the date of their onset and end.

(45) The scheme of examination is presented in Table 1.

(46) Within 4 weeks “Remedy 1” and “Remedy 2” were administrated within daily dose 2 times a day 30 minutes before meal. Evaluation of the results of therapy was performed on the 28th day of treatment. The main criterion of efficacy was the recovery of sexual activity.

(47) TABLE-US-00004 TABLE 1 Scheme of patients examination Stage I (enrollment in the study) Screening and Stage II (drug therapy) Documents and research randomization Days of treatment methods (days 0-7) 3 7 14 21 28 Informed consent for V — — — — — participation in the study CRFs V V V V V V SFM questionnaire V — — — — V State of sexual function V — — — — V questionnaire (Vakina TN 2001) Level of total serum V — — — — V testosterone HADS scale V — — — — V Mini-Mult questionnaire V — — — — — TRUS of prostate V — — — — — Consultation of urologist V — — — — — Blood and urine tests V — — — — — Evaluation of side effects — V V V V V

(48) Study results were processed using the statistical program “STATISTICA-6.0”.

(49) All 30 patients completed the study. Characteristics of patients with erectile dysfunction included in the study are presented in Table 2.

(50) TABLE-US-00005 TABLE 2 Characteristics of study patients with erectile dysfunction (n = 30) Patients Patients Patients treated treated of control by remedy 1 by remedy 2 group Values (n - 12) (n = 13) (n = 5) Age (average value) 49.6 ± 6.9 47.3 ± 5.9 47.3 ± 5.1 Family status Single —  4.8% — Married 83.4% 80.9% 80.0%.sup.  Divorced  8.3%  4.8% — Civil marriage  8.3%  9.5% 20.0%.sup.  Level of education Higher 58.3% 57.2% 60% Secondary professional 16.7% 19.0% 20% Secondary 25.0% 23.8% 20% Anthropometric parameters Trochanteric index  1.9 ± 0.03  1.9 ± 0.04  1.9 ± 0.02 Body Mass Index 25.9 ± 1.9 1.92 ± 1.9 25.0 ± 1.2 Age at the beginning of 45.0 ± 5.3 44.2 ± 5.1 43.6 ± 4.9 disease (average) Duration of disease (average) 5.2 6.7 4.8 Was the treatment conducted yes-1, no -11 yes-3, no-10 no-5 (yes, no, amount) Comorbid physic pathological disorders: Anaxiophobic 41.6% 46.1% 40% Mixed anxiety 33.3% 30.8% 40% Anxiety-depressive Adaptation disorder 25.1% 23.1% 20% Somatic diseases: CVD 33.3% 38.4% 20.0%.sup.  Diabetes  8.3%  7.6% — Smoking 41.6% 46.5% 40% Gastrointestinal 33.3% 30.7% 40% Prostate 41.6% 30.7% —

(51) Patient clinical characteristics (treatment onset with “Remedy 1” and “Remedy 2”) did not have significant differences in the experimental and control groups showed.

(52) The average age of the patients was 48.1±6.0 years, average duration of erectile disorder—5.6±2.7 years. Males with higher education (58.5%) were predominated. By family status patients were mostly married men (81.4%). The majority of the patients had weak (20%) and a weakened type of the average sexual constitution (55%).

(53) Assessment of risk factors for smoking was detected in 42.7%, higher body mass index—53.3%; cardiovascular diseases (hypertension, ischemic heart disease in history) were observed in 30.6% of patients.

(54) According to the results of clinical and psychopathological study anxiety-phobic disorder was diagnosed in 42.6%, mixed anxiety-depressive disorder—34.7%, adaptation disorder—22.7% patients. Analysis of test results by Mini-Mult scale showed high levels of hypochondria in 86.7%, depression—54.3%, psychasthenia—52.7% patients. Average scores on hypochondria scale were 62 points, psychasthenia—57 points, depression—53 points and schizoid—51 points.

(55) Sexual dysfunction in all patients included in the study manifested as difficulty in the onset or maintaining erection sufficient for satisfactory sexual intercourse in the absence of evident signs of organic pathology of sexual sphere, corresponding to ICD-10, “the lack of genital response” (F52.2).

(56) Against therapy with “Remedy 1” and “Remedy 2” in the experimental groups on the 7th day of treatment patients reported a subjective improvement in mood, increased self-esteem and confidence in their sexual opportunities, reducing tension and conflicts in family relationship, as well as increased frequency of spontaneous erections.

(57) The study of efficacy of “Remedy 1” and “Remedy 2” on sexual function of patients given clinical and dynamic changes in the level of blood testosterone revealed the following (Table 3):

(58) TABLE-US-00006 TABLE 3 Dynamics of testosterone against therapy Average totals Group 1 (n = 12) Group 2 (n = 13) Group 3 (n = 5) After After After Studied Before 28 days of Before 28 days of Before 28 days of parameters treatment treatment treatment treatment treatment treatment Total testosterone 11.8 ± 4.4 14.6 ± 5.2 14.5 ± 4.7 17.3 ± 5.6 12.9 ± 4.7 13.1 ± 5.8

(59) In group 1 with “Remedy 1” administration testosterone levels increased by 23.7%, in the 2 group with “Remedy 2”—by 19.8%.

(60) The growth of sexual activity indicators—libido and erection—with the treatment of “Remedy 1” and “Remedy 2” by the Day 28 of treatment was detected in 66.7 and 61.5% patients, respectively, average increase of libido was 28.0 and 24.3%, erection—21.4 and 17.8%, respectively. Dynamic changes of sexual activity indicators (libido and erection) and psycho-emotional state of patients with erectile dysfunction and comorbid anxiety and depressive disorders are presented in Table 4.

(61) TABLE-US-00007 TABLE 4 Results of therapy and tests performed on day 28 of treatment Average totals (in points) Group 1 Group 2 Group 3 On day 28 On day 28 On day 28 Investigated Before of Before of Before of parameters treatment treatment treatment treatment treatment treatment SFM 18.8 ± 3.2 21.9 ± 3.5* 18.4 ± 3.1 21.4 ± 3.2* 18.9 ± 2.1  19.1 ± 2.5  questionnaire Sexual function status questionnaire Libido 2.8 3.6 2.7 3.4 2.9 3.0 Erection 3.0 3.6 2.9 3.4 3.0 3.0 HADSscale Anxiety 11.2 ± 0.8  6.9 ± 0.5** 10.9 ± 1.0  7.1 ± 0.5** 11.4 ± 0.3 8.5 ± 0.5 Depression  9.1 ± 0.4  6.2 ± 0.3*  9.5 ± 0.7  6.1 ± 0.3* 10.0 ± 0.4 7.9 ± 0.8 Clinical Abs. 8 8 1 effect % 66.7 61.5 20.0 Note: *p < 0.05, **p < 0.001

(62) The therapeutic effect of the drugs was more pronounced in relatively young men in the absence of the above mentioned risk factors and expressed anxiety-depressive psychopathology disorders. It is shown by evidence of the effectiveness of the drug in the treatment of erectile dysfunction in 75.2% of cases in men under 40 years old.

(63) In the course of therapy with “Remedy 2” (from 2 to 4 days of treatment) 2 patients had transient diarrhea. It resolved spontaneously. Tolerability of “Remedy 1” and “Remedy 2” is good.

(64) Against treatment with “Remedy 1” and “Remedy 2” erectile dysfunction is common in hospital anxiety and depression, and requires adequate specific therapy.

(65) The claimed remedy is a combination of biologically active drug that is based on L-arginine, icariin (Rhaponticum carthamoides extract), Male bee brood, pollen (bee pollen), zinc citrate, vitamin B6, it has the ability to increase sexual desire and improve the quality of erections and, therefore, is a vegetable alternative to the treatment of sexual disorders in male.

(66) Use of “Remedy 1” showed an increase in the level of testosterone in the blood serum in 23.7%, “Remedy 1”—19.8% by the Day 28 of treatment.

(67) Indicators of sexual activity—libido and erection—and psycho-emotional state against “Remedy 1” and “Remedy 2” treatment by the Day 28 of treatment were detected in 66.7 and 61.5% patients, respectively. In the group of patients with “Remedy 1” average increase of libido and erection was observed in 28.0 and 21.4%, and in group 2-24.3 and 17.8% patients, respectively. There was significant improvement of mental and emotional state with 50% reduction in the level of anxiety and depression in both the first and second group of patients.

(68) The second study was carried out with all 8 components. Composition of “Remedy 3” in a daily dose was the following:

(69) TABLE-US-00008 Components Mg of active substance True or false ginseng root in terms of 9 saponins Leuzea root in terms of ecdysteroids 0.15 L-Arginine 900 Horny goat weed in terms of icariin 60 Male bee brood in terms of decenoic acid 0.6 Pollen or beebread in terms of rutin 48 Zinc citrate in terms of zinc 9 Vitamin B6 1.8

(70) Study Objective:

(71) evaluation of the efficacy of “Remedy 3” in the treatment of male sexual dysfunction.

(72) The study investigated clinical features of sexual dysfunctions in studied patients. Effectiveness of “Remedy 3” on the dynamics of testosterone, prolactin and dehydroepiandrosterone sulfate (DHEAS) levels was evaluated by the changes of the values of sexual function (libido and erection) and psycho-emotional state of studied patients.

(73) The study involved 10 men with sexual dysfunction (erectile dysfunction and decreased libido). Inclusion criteria were:

(74) 19-60 years old (age limit was associated with frequent detection in men older than 60 years of the severe cerebral organic and physical illnesses and involution processes);

(75) matching of patient's condition at the time of inclusion to diagnostic criteria of ICD 10 for F52—sexual dysfunction (absence or loss of the sexual desire (F 52.0), absence of genital response (F52.2)), accompanied by one of the following neurotic disorders: anxiety-phobic (F40); mixed anxiety-depressive disorder (F41.2) and adaptation disorder (F 43.2);

(76) absence of leading organic lesion in pathogenesis of sexual disorder.

(77) The study did not include patients with alcoholism; drug addiction; anatomical deformity of the penis; proven endocrine causes of ED; decompensated somatic diseases; use other treatment agents for ED and drugs that can cause ED.

(78) The study was conducted by the open method, without placebo control.

(79) During clinical and sexual examination severity and dynamics of sexual pathological symptoms during therapy were evaluated by clinical questionnaire “Sexual Formula for Men” (SFM), IIEF-5 questionnaire (International Index of Erectile Function), scale of assessment of sexual function (Vakina T. N. 2001) (see. appendices 1, 2, 3).

(80) Laboratory and instrumental examinations included complete blood count, urinalysis, quantitative content determination of hormones in blood serum—total testosterone, prolactin and DHEAS—by enzyme-linked immunosorbent assay, as well as transrectal prostate ultrasound. Consultative examination by urologist was performed.

(81) The mental state of the patients was determined by clinical and psychopathological method. Examination of personality characteristics was performed by Mini-Mult questionnaire. Intensity and dynamics of anxiety-depressive disorder symptoms during therapy were evaluated by Hospital Anxiety and Depression Scale (HADS).

(82) The research was conducted as follows (table 5): a preliminary study—1 week (check the inclusion and exclusion criteria, consent to participate in study, medical history, assessment of the general condition of organs and systems, laboratory tests, clinical sexual and psychological testing). Phase of treatment—4 weeks—use of “Remedy 3” at a dose of 2 tablets 3 times a day 30 minutes before meals with the registration of changes in the general condition of the patient and side effects. Final evaluation of the treatment was carried out in 28-30 days with the assessment by SFM questionnaire, scale of assessment of sexual function, hormonal tests, HADS scale, identification of drug tolerability.

(83) TABLE-US-00009 TABLE 5 Scheme of patients examination Stage I (enrollment in the study) Screening Stage II and (Treatment by Remedy 3) Documents and research randomization Days of treatment methods (days 0-7) 3 7 14 21 28 Informed consent for V — — — — — participation in the study CRF V V V V V V SFM questionnaire V — — — — V IIEF-5 questionnaire V — — — — — State of sexual function V — — — — V questionnaire (Vakina T.N. 2001) Level of total serum V — — — — V testosterone, prolactin, DHEAS HADS scale V — — — — V Mini-Mult questionnaire V — — — — — TRUS of prostate V — — — — — Consultation of urologist V — — — — — Blood and urine tests V — — — — V Evaluation of side effects — V V V V V

(84) Effectiveness evaluation was based on the dynamics of indicators of the scale of assessment of sexual function, “Sexual Formula for Men” (SFM) questionnaire, HADS scale, the results of hormone tests, evaluation of the clinical effectiveness of physician therapy.

(85) During assessment of clinical efficacy by the patient end result was defined as excellent (no complaints, resumption of sexual activity in full extent), good (considerable improvement, but still with some complaints), satisfactory (the patient noted improvement, but full recovery of sexual activity was absent), without effect.

(86) The results were processed using the “STATISCTICA-6.0” statistical program.

(87) According to the results of the study all 10 patients completed the study. General characteristics of the patients included in the study are presented in the Table 6.

(88) TABLE-US-00010 TABLE 6 Characteristics of the studied patients with sexual dysfunction (n = 10) Patients treated by EROMAX 3 Indicators (n = 10) Age (average value) 46.9 ± 5.1 Family status Single 10% Married 60% Divorced 30% Civil marriage — Level of education Higher 80% Secondary professional 20% Secondary — Anthropometric parameters  1.89 ± 0.04 Trochanteric index 26.9 ± 2.9 Body Mass Index 41.6 ± 6.0 Age at the beginning of  4.9 ± 2.3 disease (average) Was the treatment conducted yes - 4, no - 6 (yes, no, amount) Comorbid physic pathological disorders: Anxiofobic 10% Mixed anxiety-depressive 30% Adaptation disorders 60% Somatic diseases: CVD 70% Diabetes 10% Smoking 30% Gastrointestinal diseases 30% Prostate disease 40%

(89) Average age of patients was 46.9±5.1 years, average duration of sexual disorders—4.9±2.3 years. Men with higher education dominated (80%). By family status patients were mostly married men (60%). The majority of the patients had weak (50%) and a weakened type of the average sexual constitution (30%).

(90) Assessment of risk factors for smoking was detected in 30%, increased body mass index—50%; cardiovascular diseases (hypertension, ischemic heart disease in history) were observed in 70% of patients.

(91) Most of the patients had a history of significant mental and physical stress, and the clinical and psychopathological study revealed adaptation disorders in 60% patients. Analysis of test results on Mini-Mult scale showed high levels of hypochondria in 60%, depression—50%, psychasthenia—50% patients. Average scores on psychasthenia scale were 62.8 points, hypochondria—59.8 points, depression—52 points and hysteria—51 points.

(92) Sexual dysfunction in all patients included in the study manifested as decreased libido with a decrease of sexual fantasies, sexual incentives search, thoughts about the sexual side of life and the difficulties in the attack or sustain an erection sufficient for satisfactory sexual intercourse, with the absence of evident signs of organic pathology of the sexual sphere, accompanied by anxiety and depressive symptoms.

(93) The main complaints of patients reflecting the clinic of androgen according to age groups are presented in Table 7.

(94) TABLE-US-00011 TABLE 7 The main complaints of patients that are typical for clinical androgen deficiency Age groups Under 45 years Above 45 years Symptoms (n = 2) (n = 8) Genitourinary disorders decrease of libido 50% 100%  erectile dysfunction 100%  75% reduction of orgasm brightness 50% 75% Vegeto-vascular disorders Sudden redness of face, neck — 37.5%.sup.  Blood pressure fluctuations — 75% Cardialgia — 50% Dizziness — 25% Lack of air — 37.5%.sup.  Excessive sweating 50% Psychoemotional disorders Increased irritability 100%  75% Reduction of the ability to — 75% concentrate attention Reduction of cognitive function, memory Depression 50% 50% Insomnia 50 50% Reduction of “vital energy” — 25% 75% Somatic disorders Decrease of muscle mass and — 37.5%.sup.  strength Increase of adipose tissue — 75% amount Osteoporosis — 12.5%.sup.  Decreased tone and skin — 25% thickness (“flabby” skin)

(95) It is noteworthy that in the age group under 45 years decreased libido was observed in all patients (100%), with erectile dysfunction in 75% of cases (Table. 7).

(96) The analysis of erectile dysfunction according to the IIEF-5 scale showed that 1 patient (10%, 22 points) had a value within the normal range; mild erectile dysfunction was detected in 5 cases (50%, 18 points average), moderate ED—in 4 (40%, 14 points average).

(97) Against the therapy by “Remedy 3,” the majority of patients (60%) by the Day 5-7 had subjective improvement mood, increased self-esteem and confidence in their sexual opportunities, reducing tension and reducing conflict in the family relationship, as well as increased frequency of nocturnal erections.

(98) The study of the efficacy of “Remedy 3” on sexual function of patients taken into account clinical and dynamic changes in the level of testosterone, prolactin and dehydroepiandrosterone sulfate (DHEAS) in serum showed the following (Table 8):

(99) TABLE-US-00012 TABLE 8 Dynamics of testosterone, prolactin and DHEAS in serum against the therapy Investigated Before After 28 days parameters treatment of treatment Normal values P Total 11.8 ± 4.4  17.1 ± 5.7 12.1-38.3 <0.02 Testosterone* nmol/L Prolactin * 548 ± 136 285 ± 60 24.5-467 <0.02 mU/L DHEAS 1.2 ± 0.3  1.4 ± 0.7 1.0-4.2 >0.054 mg/ml

(100) Against use of “Remedy 3” there were significantly elevated levels of total testosterone (p<0.02) and DHEAS against the lowered prolactin levels (p<0.02) (the latter could also be regarded as anti-stress improving trends in the studied group of patients).

(101) Rate of growth of testosterone levels against use of “Remedy 3” was 44.9%. These changes of hormonal status helped to reduce the number of patients' complaints on vegetosovascular disorders—sudden flushing of the face, neck, increased sweating, feeling of short of breath, fluctuations of blood pressure, as well as on psycho-emotional sphere. Patients reported mood stabilization, addition of “vital energy force”, improvement of concentration, memory, normalization of sleep. The amount of adipose tissue decreased which revealed itself in a decrease of waist circumference by an average of 3.9 cm for 1 month.

(102) At the time of the control evaluation—after 4 weeks of treatment—patients had significant change in scale of sexual function assessment: libido—4.0 points versus baseline of 2.8 (p<0.02), average increase of the libido was 42.8%, erection—3.8 points versus baseline of 2.9 (p<0.032), average increase of the erection was 31%.

(103) Assessment of sexual function in accordance with the SFM questionnaire before treatment revealed general decline of male copulation cycle values. Against therapy with “Remedy 3” total score of male sexual function increased from 17.7±2.5 to 23.8±2.9 (p<0.02). Among the structural indicators of SFM mental component of the male copulation cycle improved more significantly that resulted in increase of libido and overall satisfaction with sexual intercourse in the studied patients.

(104) Dynamic changes of comorbid psychoemotional disorders parameter—anxiety and depression—of patients with sexual dysfunction are shown in Figure 3. If before treatment the average level of anxiety was regarded as a clinical one and was 11.5±0.6 points on HADS, after treatment it decreased to normal level—6.9±0.3 points (p<0.02). The average level of depression on HADS scale at the beginning of treatment was approaching to clinical one—10.8±0.5 points; at control day 28 the depression values were reduced to normal levels—6.7±0.3 (p<0.02).

(105) During therapy with “Remedy 3” (from Day 2 to Day 4 of treatment) 3 patients had transient diarrhea. It resolved spontaneously. Indicators of blood count, urinalysis, and biochemical blood tests were within the normal range before the start of treatment and at its end. Overall tolerability of “Remedy 3” was good.

(106) In evaluating the clinical efficacy of the treatment 2 (20%) patients evaluated results as “excellent”—the absence of complaints, the resumption of sexual life in full extent, 6 (60%) patients—as “good”—a considerable improvement but still with some complaints, and 2 (20%)—as “satisfactory”—improvement, but full recovery of sexual activity was absent, but the latter ones had marked improvement in the parameters of hormonal status with higher levels of total testosterone and decrease of prolactin.

(107) Thus, sexual dysfunction is common in patients with anxiety and depression and requires an adequate specific therapy. “Remedy 3” is a combined biologically active drug that is based on L-arginine, ginseng root, Leuzea root, horny goat weed extract, pollen (bee brood), zinc citrate, vitamin B6, and it is able to increase sexual desire and improve the quality of erection, and hence is a natural and safe alternative effective treatment for sexual dysfunction in males. Use of “Remedy 3” showed a significant increase of testosterone level (average increase of 44.9%) against prolactin level decrease as well as a tendency to DHEAS increase by day 28 of treatment. Parameters of sexual activity—libido and erection—against use of “Remedy 3” significantly changed: the average increase of libido was 42.8%, erection—31%. The therapy with “Remedy 3” led to stabilization of vegetative vascular system, as well as significant improvement of mental and emotional state of patients with reduction of anxiety and depressive disorders.

(108) in males. The questionnaire consists of 10 sections (marked by Roman numerals) in each section patient's responses are indicated by numbers from 0 to 4. A patient before the test is invited to complete a questionnaire, marking in each section a statement that most closely matches his condition at the time of doctor's appointment.
I. The Need for Sexual Relations
How often does the strong desire to perform sexual intercourse (regardless of the penis tension) occur:
0—Never or no more than once a year.
1—Several times a year, but not more often than once a month.
2—From two to four times a month.
3—Twice or more often in a week.
4—Every day once or more times,
II. Mood Before Sexual Intercourse
0—Strong fear of failure and, therefore, attempts have never been made.
1—Expressed uncertainty, and, therefore, I'm looking for an excuse to evade attempts.
2—Some uncertainty, but I do not evade attempt (or—I made copulation to satisfy wife, without inner motivation, or—I perform intercourse to test myself)
3—Primarily—a desire for enjoyment and having a woman; I make intercourse without fear.
4—Always just a thirst for pleasure with a woman, never feel the slightest doubts.
III. Sexual Proactivity
I perform act aimed at the immediate implementation of sexual intercourse
0—I do not perform such acts or perform them with intervals of not less than one year.
1—Several times a year, but not more than once per month.
2—Several times per month, but not more often than once a week.
3—Twice or more often in a week.
4—Every day, once or several times.
IV. Frequency of Sexual Intercourse
I manage to perform intercourse (though not quite in full form, that is, short-term or partial tension of penis)
0—I have never been able.
1—Very rare.
2—In most cases.
3—In normal situations, always.
4—In any situation and always, even if the circumstances are not favorable.
V. Tension of Penis (Erection)
0—Erection does not occur under any circumstances.
1—without sexual intercourse erection is sufficient, but at the time of sexual intercourse it weakens, penis penetration is not possible.
2—I have to use force or local manipulation to cause an erection sufficient for penetration (or erection weakens after penetration but before ejaculation).
3—Erection is incomplete but the penetration is possible effortlessly.
4—Erection occurs in all conditions, even the most unfavorable.
VI. The Duration of Sexual Intercourse
Ejaculation occurs:
0—does not occur under any circumstances.
0.5—occurs at every intercourse, intercourse is prolonged; sometimes it has exhausting character.
1—before the penis penetration or at the time of penetration.
2—in a few seconds after penetration.
2.5—approximately within 15-20 movements.
3-4—in 1-2 minutes or longer (indicate the approximate duration).
VII. The Frequency of Sexual Emission
Ejaculation occurs with intercourse (or nocturnal emissions, masturbation, etc.) on average
0—does not occur or occurs no more than once a year.
1—several times a year, but not often than once a month.
2—several times a month, but not often than once a week.
3—twice or more often in a week.
4—every day, one or more times.
VIII. The Mood After Sexual Intercourse (or Failed Attempt)
0—Extreme depression, a feeling if disaster (or aversion to his wife).
1—Disappointment.
2—Indifference (or some sediment from the understandings that a woman feels dissatisfied).
3—Satisfaction and pleasant fatigue.
4—Complete satisfaction and elation.
IX. Measuring the Success of Sexual Life
0—Women do not want to have sex with me
1—Women express criticisms.
2—Sexual life is going on with varying degrees of success.
3—Sexual life is generally successful.
4—I am able to satisfy a woman under all circumstances.
X. Duration of Sexual Disorders
0—From the beginning of sexual activity.
1—Longer than half a year.
2—Less than half a year.
3—Currently there are no problems but they occurred in the past (particularly at the beginning of sexual activity).
4—I do not know what is it having difficulties in sexual life.
The numbers 0, 1, 2 in each of the ten parameters reflect different degrees of decreased sexual function, 3—above average rate for middle-aged men, 4—strong sexual constitution or a period of youthful hypersexuality.
Structural indicators reflect: I—the state of preliminary readiness associated with neuroendocrine libido assurance; II, III—the state of psychic sphere, which is expressed in the mood before coitus, sexual activity. Indicators IV, V reflect the implementation of the objective parameters of sexual activity: the frequency of coitus, the quality of erections. Indicators VII and VI objectively characterize the ejaculatory function. Indicators VIII and IX represent a subjective assessment of sexual intercourse by the man and his partner.
The SFM analysis takes into account each of received responses, and then their numerical expressions are summarized. Thus for a statistically average norm SFM is 30. For the patients with sexual disorders and false sexual disorders SFM values differ from the average downwards.

(109) TABLE-US-00013 APPENDIX 2 IIEF-5 questionnaire (International Index of Erectile Function, variant with 5 questions) How do you Very low Low Medium High Very evaluate your 1 2 3 4 high confidence in that 5 you can achieve and maintain an erection? In case of erection Sexual Almost Several Sometimes In most Almost due to sexual activity never or times (about a cases always stimulation how is absent never (far less half of (more or often do you have 0 1 than cases) than a always an erection strong half of 3 half of 5 enough for penis cases) cases) penetration into the 2 4 vagina? In case of sexual There were Almost Several Sometimes In the Almost intercourse how no attempt never or times (about a most always often do you for sexual never (far less half of cases or manage to maintain intercourse 1 than cases) (more always an erection after 0 half a 3 than a 5 penis penetration cases) half a into the vagina? 2 cases) 4 In case of sexual There were Extremely Very Difficult Quite Not intercourse to what no attempt difficult difficult 3 difficult difficult extent do you find for sexual 1 2 4 5 it difficult to intercourse maintain an 0 erection to complete intercourse? In case of sexual There were Almost Several Sometimes In the Almost intercourse no attempt never or times (about a most always attempts how often for sexual never (far less half of cases or you were satisfied? intercourse 1 than cases) (more always 0 half of 3 than a 5 cases) half of 2 cases) 4 All questions are relating to the state within the last 6 months. Total score     
Norm—no ED—21-25 points, mild ED—16-20 points, moderate ED—11-15 points and significant ED—5-10 points.

(110) TABLE-US-00014 APPENDIX 3 Scale of evaluation of sexual function (Vakina T. N., 2001) Erection Libido Before Before treat- treat- Symptoms ment After Symptoms ment After Complete absence 1 1 Complete absence 1 1 of libido Erection atony 2 2 Marked decrease of 2 2 with the libido (rare impossibility of intercourses with spontaneous the steady rhythm penetration of sexual life completely broken) Erection atony 3 3 Moderate decrease 3 3 with the of libido possibility of (steady rhythm of spontaneous sexual life is penetration changed, but sexual breaking the activity is steady rhythm of maintained) a sexual life Erection atony 4 4 Slight decrease of 4 4 not affecting the libido (does not steady rhythm of break the rhythm of a sexual life sexual life) Normal adequate 5 5 Normal libido 5 5 erection Total
Questionnaire includes 10 questions designated by the numbers. Each question has 6 possible answers that have a rating from 1 to 5. One corresponds to an extreme degree of dysfunction, five—the maximum of the function intensity, which is typical for individuals with a strong type of sexual constitution.

(111) TABLE-US-00015 APPENDIX 4 QUANTIFICATION OF HORMONES IN BLOOD SERUM Test method: enzyme-linked immunosorbent test Reference Units of No Hormones ranges measurement 1 Total testosterone mIU/L 12.1-38.3 2 DHEAS nmol/L 1.0-4.2 3 Prolactin μg/ml 24.5-467 
Testosterone is the main male sex hormone, mainly synthesized in the testes by Leydig cells (95%). A very small amount of testosterone is produced by adrenals (5%). The classic effects of testosterone include: androgen effects—the growth and development of sex organs, expression of secondary sexual features (hair growth on the face, body, limbs, as well as bald patches and baldness formation), erectile function; psychophysiological—libido, the formation of stereotypes of sexual behavior (aggressive, warlike behavior), mood, psycho-stimulating effect; reproductive—maintenance of spermatogenesis; anabolic—maintaining muscle mass (including myocardiocytes), stimulation of the synthesis of organ-specific proteins in kidneys, liver, sebaceous and sweat glands, maintaining bone density; antigonadotropic—suppression of gonadotropins secretion; hematopoietic—stimulation of erythropoietin generating in the kidneys, stimulation of erythropoiesis in the bone marrow.
Common symptoms of androgen deficiency are disorders of sexual function (decreased libido, erectile, orgasm, ejaculation dysfunction, decreased fertility of ejaculate) and vegetative-vascular disorders (hot flashes, “tides”, blood pressure fluctuations, cardialgia, feeling of short of breath), psycho-emotional disorders (irritability, decreased overall health and performance, decreased memory and attention, insomnia, depression), somatic disorders (reduction of muscle mass and strength, increase of adipose tissue amount, bone loss, gynecomastia, visceral obesity, thinning of the skin).
In recent years the pathophysiological mechanisms of androgen impact on erections have been studied. Biochemical studies data show that nitric oxide synthase is an androgen-dependent enzyme; in case of hypogonadism this enzyme deficiency leads to reduction of the synthesis and release of nitric oxide from the vascular endothelium of the corpora cavernosa and, therefore, to inadequate vasodilation due to a deficiency of cyclic guanosine monophosphate (cGMP) in the cavernous tissue.
In several studies it was shown that a decrease of testosterone concentration results in increased deposition of fat cells in the corpora cavernous which causes a degeneration of the smooth muscle cells which results in poor elasticity of cavernous tissue with formation of venous cavernous erectile insufficiency.
Kalinichenko S. Y. summarized data on the effect of androgen deficiency on erectile function: Reduction of relaxation of smooth muscle cells of the cavernous tissue; Decrease of nitric oxide production; Increased apoptosis of smooth muscle cells; Increased number of fat cells.

(112) However, testosterone deficiency does not always affect the mechanism of erection, but it is a pathogenic factor in libido reduction. Numerous studies of the effects of testosterone on the individual components of the copulative cycle showed that the most significant positive correlation was found between its concentration in blood and sexual desire (Jordan W. et al. 1998, Clopper, 1993). It is assumed that androgens increase desire by increasing the sensitivity of certain centers in the limbic system and hypothalamus, as well as by increasing overall activity and vitality of the body due to the stimulating effect of androgens on metabolism. This is confirmed by the fact that testosterone preparations are the most effective drugs to increase libido and stimulate the orgasmic experiences intensity.

(113) A lack of androgens leads to a decrease of sexual interest and activity. Effect on erectile function is more complicated (Kwan et al., 1983). Therefore, an erection could be observed over the years (Heim, 1981) after castration. Similarly, the gradual recovery of male sexual behavior in case of chronic androgen deficiency does not immediately occur under the influence of testosterone replacement therapy.

(114) Prolactin is a hormone involved in the growth of the prostate. Prolactin (PRL) is necessary to maintain maximal steroidogenic activity of Leydig cells in the presence of luteinizing hormone (LH); it increases the number of receptors for LH.

(115) Under physiological conditions, stimulation of PRL release occurs during sleep, stress, physical activity, receiving protein foods, hypoglycemia. PRL is often called a stress hormone, although the effect of mental and psychological stress on its release is not clearly demonstrated. Pathological hyperprolactinemia may be a manifestation of independent hypothalamic pituitary disease or as well a syndrome in the structure of various endocrinopathies, somatogenic and neuropsychiatric disorders (acromegaly, primary hypothyroidism, chronic renal failure, chronic prostatitis, hepatic cirrhosis).

(116) For men, symptoms of hyperprolactinemia include reduced or absent libido and potency, reduction of secondary sexual features, infertility due to oligospermia and gynecomastia.

(117) Chronic hyperprolactinemia in males is associated with inhibited secretion of gonadotropin-releasing hormone (GnRH), and hence of gonadotropic secretion, resulting in reduced total testosterone in serum.

(118) It is supposed that direct depletion of dopamine (DA) in dopaminergic neurons may play a major role in the male copulation behavior, especially in reducing libido, concomitant with hyperprolactinemia.

(119) DHEAS (dehydroepiandrosterone sulfate) is a secondary source of testosterone in men, produced primarily by the adrenal glands. DHEAS has relatively weak androgenic activity which for non-sulfonated hormone is about 10% of the testosterone level. However, its biological activity is enhanced by the relatively high concentration of serum—a hundred times superior to testosterone—as well as due to the weak affinity for steroid-binding β-globulin. This hormone is a precursor of both estrogen and testosterone.

(120) DHEAS (and DHEA) are present in the tissues of the brain and are regarded as a neurosteroid involved in the regulation of behavior and psychophysiological reactions (stress reactions, intelligence, memory, attention, sleep). Decrease of circulating levels of DHEA and, accordingly, the ratio of DHEA/cortisol is associated with the CNS disorders such as depression, memory disorders, chronic fatigue syndrome, decreased libido, Alzheimer's disease.

(121) By the age of 50, DHEA levels are reduced by 30% compared with those of men of the age of 30. It is widely believed that the decrease of DHEAS occurs in parallel with the decrease of well-being, and that exogenous DHEA substitution leads to an improvement in quality of life parameters.

(122) Appendix 5—Hospital Anxiety and Depression Scale (HADS)

(123) In clinical practice HADS scale is used to identify and assess the severity of anxiety—depressive disorders in screening studies, as well as to assess the effectiveness of psycho corrective therapy. Scale is filled in by the patient alone within 15-20 min.

(124) HADS contains 14 symptoms and consists of two subscales—anxiety (A), and depression (D). Anxiety assessment includes odd items; depression—even ones. Each parameter corresponds to four choices, reflecting its presence and severity.